Information  X 
Enter a valid email address

Evgen Pharma PLC Ord 0.25P (EVG)

Related News

15-Jun-2020 08:16 AM

Evgen Pharma reports slightly wider losses on higher costs

Pharmaceutical company Evgen Pharma reported slightly wider losses as a reduction in payroll costs were offset by increased professional fees and business development costs. For the year ended 31 March 2020, pre-tax losses widened to £2.7m from &
17-Dec-2019 09:53 AM

Evgen Pharma books loss at it proves up drug candidates

Evgen Pharma booked a first-half loss as it continued to develop its portfolio of drug candidates. Pre-tax losses for the six months through September amounted to £1.61m, compared to losses of £1.79m on-year. Operational highlights for the y
13-Jun-2019 07:47 AM

Evgen Pharma reports slight uptick in losses on increased costs

Drug development company Evgen Pharma reported a slight increase in pre-tax losses as costs inched higher amid continued clinical expenditure on trials of its breast cancer drug. For the year ended 31 March 2019, pre-tax losses widened to £3.12m f
18-Apr-2019 08:30 AM

Broker Forecast - finnCap issues a broker note on Evgen Pharma Plc

finnCap today reaffirms its corporate investment rating on Evgen Pharma Plc (LON:EVG) and cut its price target to 35p (from 45p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
02-Apr-2019 09:20 AM

Broker Forecast - finnCap issues a broker note on Evgen Pharma Plc

finnCap today initiates coverage of Evgen Pharma Plc (LON:EVG) with a corporate investment rating and price target of 45p. Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
13-Jun-2018 02:37 PM

Evgen Pharma losses narrow as expenses fall

Evgen Pharma, which is focused on the treatment of cancer and neurological conditions, said annual losses narrowed to £3.0m, from £3.6m, on lower operating expenses. The company recently released encouraging data for a sulforaphane-based trea
25-Apr-2018 01:50 PM

Broker Forecast - Northland Capital issues a broker note on Evgen Pharma Plc

Northland Capital today reaffirms its buy investment rating on Evgen Pharma Plc (LON:EVG) and set its price target at 113p. Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
13-Dec-2017 08:07 AM

Evgen Pharma collaboration with King's College London

Evgen Pharma has announced a collaboration with King's College London ("King's") to advance SFX-01, the company's lead product candidate, towards the clinic as a therapy for ischaemic stroke. In a programme of work funded by the
08-Dec-2017 07:56 AM

Evgen Pharma losses stable; raises £2.3m

Evgen Pharma posts a total comprehensive loss of £1.7m for the six months to the end of September - unchanged from a year ago. The net cash outflow for the period (before short-term investment movements) was also £1.7m (30 Sep 2016: £
04-Oct-2017 07:32 AM

Evgen Pharma granted first European patent

Evgen Pharma, a clinical stage drug development company focused on the treatment of cancer and neurological conditions, has announced the grant of the first European patent for SFX-01, the company's lead product. SFX-01 is a synthetic version of the
26-Jul-2017 09:16 AM

Evgen Pharma 'progressing well'

Evgen Pharma's current year is progressing well and SFX-01, its lead product candidate, continues to be tested in two phase II trials in different indications, breast cancer and subarachnoid haemorrhage, shareholders at today's annual general m
11-Jul-2017 01:12 PM

Evgen confirms details of SFX-01 study

Evgen Pharma has confirmed that the Company's lead product, SFX-01, will be tested against triple negative breast cancer (TNBC) in new preclinical research at the Manchester Cancer Research Centre. The Company said this initiative is to be funded by
13-Jun-2017 08:09 AM

Evgen Pharma losses widen

Operating losses at Evgen Pharma rose to £3.7m for the year to the end of March - up from £2.4m last time. The group said the financial performance was in line with expectations and the total loss for the year was unchanged at £3.1m, i
14-Feb-2017 01:58 PM

Evgen granted US patent for SFX-01

Evgen Pharma has announced that the United States Patent and Trademark Office has granted a patent that significantly broadens and extends the Company's intellectual property around its lead product, SFX-01. Dr Stephen Franklin, CEO of Evgen Pharma,
13-Feb-2017 08:27 AM

Evgen signs services agreement with APTrans

Evgen Pharma, a clinical stage drug development company focused on cancer and neurological conditions, has signed a services agreement with APTrans to support the ongoing development of lead product, SFX-01. APTrans is a consortium of drug development
17-Jan-2017 08:53 AM

Evgen Pharma doses first patient in breast cancer trial

Evgen Pharma has confirmed that the first patient has been dosed in the company's phase II clinical trial of SFX-01 in breast cancer. The STEM (SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer) trial is investigating SFX-01 in comb
11-Jan-2017 08:00 AM

Evgen Pharma confirms positive review of SAS trial

Evgen Pharma, a clinical stage drug development company focused on the treatment of cancer and neurological conditions, has received a positive interim safety review from the independent Data Safety Monitoring Board of its phase II double-blind, placebo-c
17-Nov-2016 03:09 PM

Evgen Pharma schedules interims

Evgen Pharma will announce its interim results for the half year ended 30 September on 5 December. At 3:09pm: (LON:EVG) Evgen Pharma Plc share price was 0p at 23p Story provided by StockMarketWire.com...
25-Aug-2016 11:10 AM

Broker Forecast - Northland Capital issues a broker note on Evgen Pharma Plc

Northland Capital today reaffirms its buy investment rating on Evgen Pharma Plc (LON:EVG) and raised its price target to 97p (from 79p). Story provided by StockMarketWire.com...
24-Aug-2016 03:27 PM

Evgen Pharma gets FDA orphan designation

The US Food & Drug Administration has granted Evgen Pharma orphan drug designation for the use of stabilised sulforaphane for the treatment of subarachnoid haemorrhage. The company's SFX-01, a synthetic and stabilised version of sulforaphane, is cu
17-Aug-2016 07:37 AM

Evgen Pharma gets go ahead for breast cancer trial

Evgen Pharma, a clinical stage drug development company focused on the treatment of cancer and neurological conditions, has received clinical trial approval from the UK's regulatory agency for the start of a phase II clinical trial of SFX-01 in breas
31-May-2016 09:16 AM

Evgen Pharma losses widen

Evgen Pharma posts a total loss of GBP3.1m for the year to the end of March (31 March 2015: GBP2.3m), reflecting higher activity levels post admission to AIM. The company said this was in line with expectations and the loss per share fell to 6.29p from
03-May-2016 09:42 AM

Evgen Pharma Plc to present at the SHARES Investor Evening in London on 19th May

Stephen Franklin, Chief Executive of Evgen Pharma (EVG) (LSE:EVG) will be giving a briefing at the SHARES Investor Evening on 19th May 2016. It will take place in London at an investor evening being organised by SHARES Magazine; the event is supported by
03-May-2016 07:58 AM

Evgen Pharma doses first patient in stroke drug trial

Evgen Pharma says the first patient has been dosed in the company's phase II clinical trial of SFX-01 in aneurysmal subarachnoid haemorrhage, a form of stroke. SFX-01 is a synthetic version of sulforaphane, a known neuroprotective and anti-cancer ag
04-Jan-2016 07:25 AM

Evgen Pharma appoints chief medical officer

Evgen Pharma, a clinical stage drug development company focused on the treatment of cancer and neurological conditions, has appointed Dr Hamina J Patel MB BCh MSc MRCPI as chief medical officer. Patel is a pharmaceutical executive with more than 15 year
 
Headlines
Top categories
Company finder
Forthcoming announcements

a d v e r t i s e m e n t